Patients can be classified into subgroups based on how susceptible they are to certain diseases, how those diseases will develop, or how they’ll respond to particular treatments. This information can then be used to predict what the most effective course of action will be. Companion Diagnostics are tools employed to identify those patients who are most likely to benefit from a particular therapeutic product, highlight those at increased risk for serious side effects, and monitor treatment response.

But what about those tasked with bringing precision medicine tests and treatments to the market? What are they doing, what challenges do they face, and how are they working with stakeholders within the wider healthcare ecosystem? We’ll follow the journey of developing a companion diagnostic from discovery through commercialization and answer those questions in this informative forum. Please come prepared with your questions.

Sponsored by the Medtech/Digital Health working group.

NOTE: As MassBio transitions to virtual events, we are striving to make them as inclusive as possible given the challenges and restrictions inherent in virtual events. Thank you for your understanding.